In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q1 2011

Executive Summary

For the first three months of 2011, medical device companies raised $733 million, with venture rounds bringing in $494 million. Two-thirds of the $3.9 billion in M&A activity came from Terumo's monstrous $2.6 billion cash takeover of US blood processing equipment maker CaridianBCT Holding. Buoyed by Opko Health's $105 million follow-on, the FOPO category represented almost half of the first quarter's in vitro diagnostics/research $370 million total. The stand-out IVD acquisition was Danaher's $6.8 billion takeover of publicly traded Beckman Coulter.
Advertisement

Related Content

Quest Highlights Diagnostics Pipeline As Key Component Of Celera Purchase
Terumo Will Top Blood Transfusion Device Space With $2.6 Billion Acquisition
Quest Diagnostics Snags Thermo Fisher’s Neuro Testing Lab Biz For $740 Mil.
Danaher Buys Beckman: Fixing Quality Issues, Cutting Costs Are Priorities
Alzheimer's Dx: An Essential Piece of the Puzzle
With Genoptix, Novartis Continues Its Diagnostics Build-up
Boston Scientific Buys Atritech For Watchman Stroke Prevention Device
J&J Snaps Up Rare Cell Capture And Analysis Technology From Mass General
Boston Scientific Lays Out Near-Term Growth Plan
CardioDx: Bringing Molecular Diagnostics Into the Cardiovascular Arena

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003661

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel